Citi keeps a Buy rating on Mirum Pharmaceuticals (MIRM) with a $72 price target after the company reported interim data for its Phase 2b VANTAGE study of volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis. Through 28 weeks of treatment, patients taking either 80mg or 20mg twice daily reported a placebo-adjusted 2.51-point reduction in their ItchRO scores as compared to baseline, the analyst tells investors in a research note. The firm says that while volixibat is slightly behind in clinical development, its efficacy profile “demonstrate best-in-class potential for the largely unpenetrated PBC market.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
- Mirum Pharmaceuticals Reports Robust Q1 2025 Growth
- Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating
- Mirum Pharmaceuticals Reports Strong Q1 2025 Results
- Mirum Pharmaceuticals reports Q1 EPS (30c), consensus (27c)